Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2023

Bristol Myers Squibb - The Changing Paradigm of Melanoma Treatment: A Clinical Update for 2023

Panel Discussion: Factors Impacting Treatment Selection for Resectable Melanoma

Date

23 Oct 2023

Session

Bristol Myers Squibb - The Changing Paradigm of Melanoma Treatment: A Clinical Update for 2023

Topics

Tumour Site

Melanoma

Presenters

All Speakers

Authors

E. Muñoz Couselo1, S. Patel2, D. Schadendorf3, A. Speakers4

Author affiliations

  • 1 Medical Oncology Department, Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 2 Melanoma Medical Oncology Department, MD Anderson Cancer Center, 77030 - Houston/US
  • 3 Department Of Dermatology - Hautklinik, WTZ - Westdeutsches Tumorzentrum Essen, 45147 - Essen/DE
  • 4 ESMO - European Society for Medical Oncology, GX11 1AA - Lugano/CH

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and Introduction

Presenter: Eva Muñoz Couselo

Session: Bristol Myers Squibb - The Changing Paradigm of Melanoma Treatment: A Clinical Update for 2023

Resources:

Webcast

Summary and Close

Presenter: Eva Muñoz Couselo

Session: Bristol Myers Squibb - The Changing Paradigm of Melanoma Treatment: A Clinical Update for 2023

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.